Flow FL-100
Flow Neuroscience AB · Decision date Jul 14, 2026
What did the FDA approve?
FDA records P230024/S001 as a supplement to PMA P230024, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 14, 2026.
FDA approval order statement
approval for minor device design changes, editorial and maintenance updates to existing firmware, server and application documentation, clarification updates to accessory pad specifications, and a minor mechanical design change.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Jul 14, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230024/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Flow Neuroscience AB
- Product code
- JXK
- Decision code
- APPR
- Decision date
- Jul 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cranial electrotherapy stimulator to treat depression.
- Applicant
- Flow Neuroscience AB
- Product code
- JXK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230024 · Original PMA
Flow FL-100
P230024/S001 received
Application receipt date recorded by FDA.
P230024/S001 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P230024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Flow FL-100P230024 | Flow Neuroscience AB | PMA approval | Dec 8, 2025 | FDA |
Explore the linked device profile
Other records with product code JXK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProlivRx SystemP250010 | Neurolief , Ltd. | PMA approval | Dec 31, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Flow Neuroscience AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 470 Ramona St., Palo Alto, CA, 94301
Sources and methodology
- Original FDA record: P230024/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
